Literature DB >> 8452354

Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins.

K M Wasan1, G A Brazeau, A Keyhani, A C Hayman, G Lopez-Berestein.   

Abstract

The role of liposome composition and temperature in the distribution of amphotericin B (AmB) with serum lipoproteins and the role of particle charge in AmB transfer to serum lipoproteins were determined. Serum obtained from healthy volunteers was incubated with known concentrations of AmB or different liposomal formulations of AmB (1 to 100 micrograms/ml) at 37 degrees C for various time intervals (5, 10, 20, 30, 45, and 60 min). After each interval, serum was removed and separated into high-density lipoprotein (HDL) and low-density lipoprotein (LDL) fractions by an LDL-direct assay. The distribution of AmB (Fungizone) at 5 min through 1 h of incubation at 25 degrees C remained constant and was similar in the HDL and LDL fractions. At 37 degrees C, at 5 through 45 min of incubation, 54 to 61% of AmB was recovered in the HDL fraction; however, at 1 h more than 75% of the AmB concentration was recovered in the HDL fraction. In contrast, 87.5 to 92% AmB was recovered in the HDL fraction throughout the incubation when negatively charged liposomal AmB (dimyristoylphosphatidylcholine [DMPC]:dimyristoylphosphatidylglycerol [DMPG], 7:3 [wt/wt]) was used. With positively charged liposomes, 75 to 87.7% of AmB was recovered in the HDL fraction through the different time points studied. AmB incorporated into DMPC (neutral) and DMPG (negative) liposomes, and AmB was distributed in an HDL:LDL ratio of 6:4 following 1 h of incubation. Ninety percent of AmB and 80% of the lipid were found in the HDL fraction in a 3:1 molar DMPG:AmB ratio and in the LDL fraction in a 6:1 molar ratio. Lipid charge and temperature play a role in AmB distribution into serum lipoproteins. AmB and DMPG may contransfer as an intact drug-lipid complex to serum lipoproteins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452354      PMCID: PMC187647          DOI: 10.1128/AAC.37.2.246

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

Review 1.  On the anatomy of amphotericin B-cholesterol pores in lipid bilayer membranes.

Authors:  T E Andreoli
Journal:  Kidney Int       Date:  1973-11       Impact factor: 10.612

2.  Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys.

Authors:  H Kim; D Loebenberg; A Marco; S Symchowicz; C Lin
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

3.  Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B.

Authors:  G Lopez-Berestein; R Mehta; R L Hopfer; K Mills; L Kasi; K Mehta; V Fainstein; M Luna; E M Hersh; R Juliano
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

4.  Distribution and activity of amphotericin B in humans.

Authors:  K J Christiansen; E M Bernard; J W Gold; D Armstrong
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

5.  Interaction of plasma proteins and lipoproteins with amphotericin B.

Authors:  J Brajtburg; S Elberg; J Bolard; G S Kobayashi; R A Levy; R E Ostlund; D Schlessinger; G Medoff
Journal:  J Infect Dis       Date:  1984-06       Impact factor: 5.226

6.  Direct determination of lipoprotein cholesterol distribution with micro-scale affinity chromatography columns.

Authors:  C L Bentzen; K J Acuff; B Marechal; M A Rosenthal; M E Volk
Journal:  Clin Chem       Date:  1982-07       Impact factor: 8.327

7.  Inhibition of the interaction between lipoproteins and amphotericin B by some delivery systems.

Authors:  J Barwicz; R Gareau; A Audet; A Morisset; J Villiard; I Gruda
Journal:  Biochem Biophys Res Commun       Date:  1991-12-16       Impact factor: 3.575

8.  Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer.

Authors:  G Lopez-Berestein; L Kasi; M G Rosenblum; T Haynie; M Jahns; H Glenn; R Mehta; G M Mavligit; E M Hersh
Journal:  Cancer Res       Date:  1984-01       Impact factor: 12.701

9.  Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits.

Authors:  M H Koldin; G S Kobayashi; J Brajtburg; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

10.  Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans.

Authors:  G Lopez-Berestein; M G Rosenblum; R Mehta
Journal:  Cancer Drug Deliv       Date:  1984
View more
  30 in total

1.  Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins.

Authors:  J R Rose; M A Mullarkey; W J Christ; L D Hawkins; M Lynn; Y Kishi; K M Wasan; K Peteherych; D P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Amphotericin B delivery from bone cement increases with porosity but strength decreases.

Authors:  Chris Kweon; Alex C McLaren; Christine Leon; Ryan McLemore
Journal:  Clin Orthop Relat Res       Date:  2011-11       Impact factor: 4.176

3.  Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin.

Authors:  K M Wasan; R E Morton
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

4.  Cyclosporine transfer from low- and high-density lipoproteins is partially influenced by lipid transfer protein I triglyceride transfer activity.

Authors:  K M Wasan; R Subramanian; J W Chou; M Ramaswamy; P H Pritchard
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

5.  Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma.

Authors:  K M Wasan; M Ramaswamy; S M Cassidy; M Kazemi; F W Strobel; R L Thies
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

6.  Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B.

Authors:  K M Wasan; M G Rosenblum; L Cheung; G Lopez-Berestein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

7.  In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid.

Authors:  V Joly; R Farinotti; L Saint-Julien; M Chéron; C Carbon; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

8.  Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses.

Authors:  J Brajtburg; S Elberg; G S Kobayashi; J Bolard
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis.

Authors:  K M Wasan; J S Conklin
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

10.  Effect of intralipid infusion on serum high- and low-density lipoprotein cholesterol, lecithin:cholesterol acyltransferase, and lipoprotein lipase in tumor-bearing rats.

Authors:  K M Wasan; V B Grossie
Journal:  Experientia       Date:  1995-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.